- Home
- FND vs GMAB Comparison
FND vs GMAB Comparison
Compare FND & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FND
- GMAB
- Stock Information
- Founded
- FND 2000
- GMAB 1999
- Country
- FND United States
- GMAB Denmark
- Employees
- FND N/A
- GMAB N/A
- Industry
- FND RETAIL: Building Materials
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- FND Consumer Discretionary
- GMAB Health Care
- Exchange
- FND Nasdaq
- GMAB Nasdaq
- Market Cap
- FND 10.2B
- GMAB 12.1B
- IPO Year
- FND 2017
- GMAB N/A
- Fundamental
- Price
- FND $94.30
- GMAB $22.34
- Analyst Decision
- FND Hold
- GMAB Buy
- Analyst Count
- FND 18
- GMAB 9
- Target Price
- FND $104.56
- GMAB $40.71
- AVG Volume (30 Days)
- FND 1.7M
- GMAB 1.9M
- Earning Date
- FND 02-20-2025
- GMAB 02-12-2025
- Dividend Yield
- FND N/A
- GMAB N/A
- EPS Growth
- FND N/A
- GMAB 83.82
- EPS
- FND 1.90
- GMAB 16.85
- Revenue
- FND $4,455,770,000.00
- GMAB $2,988,286,182.00
- Revenue This Year
- FND $1.36
- GMAB $18.78
- Revenue Next Year
- FND $9.66
- GMAB $14.98
- P/E Ratio
- FND $49.63
- GMAB $13.00
- Revenue Growth
- FND 0.95
- GMAB 30.67
- 52 Week Low
- FND $89.06
- GMAB $18.64
- 52 Week High
- FND $135.67
- GMAB $31.88
- Technical
- Relative Strength Index (RSI)
- FND 40.88
- GMAB 65.39
- Support Level
- FND $91.92
- GMAB $18.74
- Resistance Level
- FND $102.49
- GMAB $22.55
- Average True Range (ATR)
- FND 4.25
- GMAB 0.46
- MACD
- FND -0.62
- GMAB 0.39
- Stochastic Oscillator
- FND 18.31
- GMAB 94.64
About FND Floor & Decor Holdings Inc.
Floor & Decor Holdings Inc operates as a specialty retailer in the hard surface flooring market. Its stores offer a range of tile, wood, laminate, and natural stone flooring products, as well as decorative and installation accessories at everyday low prices. It appeals to a variety of customers including professional installers, commercial businesses, Do It Yourself (DIY) customers, and customers who buy the products for professional installation. Geographically, the group has a presence in the United States region and also offers its product through an e-commerce site.
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.